🇺🇸 FDA
Patent

US 12414953

Selective inhibitors of protein arginine methyltransferase 5 (PRMT5)

granted A61KA61K31/519A61P

Quick answer

US patent 12414953 (Selective inhibitors of protein arginine methyltransferase 5 (PRMT5)) held by Prelude Therapeutics, Incorporated expires Mon Sep 11 2045 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
Prelude Therapeutics, Incorporated
Grant date
Tue Sep 16 2025 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Sep 11 2045 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
70
CPC classes
A61K, A61K31/519, A61P, A61P35/00